OCUGEN, INC. ANNOUNCES POSITIVE SCIENTIFIC ADVICE FROM THE EUROPEAN MEDICINES AGENCY RELATED TO THE APPROVAL PATHWAY FOR OCU410ST—MODIFIER GENE THERAPY FOR STARGARDT DISEASE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.